Sanctuary Advisors LLC Makes New $1.14 Million Investment in ANI Pharmaceuticals, Inc. $ANIP

Sanctuary Advisors LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 13,756 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,139,000. Sanctuary Advisors LLC owned approximately 0.06% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the first quarter worth about $28,000. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. boosted its stake in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ANIP shares. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the transaction, the vice president owned 74,424 shares of the company’s stock, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total transaction of $231,876.00. Following the completion of the transaction, the chief financial officer owned 174,693 shares in the company, valued at approximately $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 24,387 shares of company stock valued at $1,947,625. 8.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $73.51 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock’s 50 day moving average price is $79.81 and its 200 day moving average price is $78.69. The firm has a market cap of $1.69 billion, a P/E ratio of 15.84 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.